In the quest to improve healthcare, new and innovative medicines garner a lot of attention, but making better use of existing medicines is just as important. This can, for instance, mean understanding better which patients benefit from a particular treatment or tackling problems with adherence to medication. This field is known as rational pharmacotherapy.
In 2010, the Netherlands based Organisation for Health Research (ZonMw) prepared a report for the ministry of VWS on identified knowledge gaps in the field of rational pharmacotherapy. In response, the ministry commissioned ZonMw to set up the Rational Pharmacotherapy programme, known in Dutch as the programme ‘Goed Gebruik Geneesmiddelen (GGG)’. The programme was launched in 2012 to better understand and promote rational pharmacotherapy in practice. Up to May 2017, the programme has allocated €45.5m.
In 2017, five years after the launch of the programme, ZonMw commissioned the Technopolis Group to conduct an external interim evaluation, covering 2012 until mid-2017. The purpose of this evaluation was to assess the efficiency and effectiveness of the GGG-programme. The evaluation drew upon primary and secondary programme level data, (group) interviews, a survey among project leaders, and a review of selected projects. An independent committee of experts supported the evaluation process by interpreting and contextualising findings and by formulating conclusions and recommendations. The evaluation is presented in this underlying report by Technopolis Group
The impact of collaboration: the value of UK medical research to EU science and health
The UK has a strong medical research community; the country’s withdrawal from the European Union (EU) can therefore be expected to have implications not only for the UK, but also for EU science and health. To better understand the UK’s contribution to medical research and patient health in the EU, a new study was commissioned…View report
Mid-term evaluation of the second Programme for Global Health and Vaccination Research (GLOBVAC2)
Technopolis recently completed its evaluation of the Global Health and Vaccination (GLOBVAC) research programme for the Research Council of Norway. Each year, the GLOBVAC research programme awards approximately €13 million in funding to research seeking to improve health for poor people in low and lower-middle income countries. The largest contributor is the Norwegian Agency for Development…View report
Evaluative study on the Cross-Border Healthcare Directive
In 2011, the Cross-border Healthcare Directive introduced a general framework to clarify patients’ rights with regard to accessing cross-border healthcare provision; guarantee the safety, quality and efficiency of care that they will receive in another EU Member State; and promote cooperation between Member States on healthcare matters. Member States had to pass their national laws…View report